Rentokil Initial H2 Earnings Call Highlights
Belite Bio aims for U.S. launch of tinlarebant in early 2027 after Phase III trial showed 36% lesion growth reduction in Stargardt disease, with NDA filing planned for Q2 2026.
6 Articles
6 Articles
SES AI Q4 Earnings Call Highlights
SES AI (NYSE:SES) reported sharply higher revenue in 2025, driven by the final contributions from electric-vehicle development services for Honda and Hyundai and by the initial revenue contribution from its energy storage acquisition, UZ Energy. Management also outlined a strategy centered on three
Belite Bio Q4 Earnings Call Highlights
Belite Bio (NASDAQ:BLTE) used its fiscal fourth quarter and full-year 2025 earnings call to outline regulatory and commercialization plans for tinlarebant in Stargardt disease, provide updates across its clinical portfolio, and review a sharply expanded cash position following multiple financings. DRAGON phase III results and next clinical steps Management highlighted December’s top-line readout from the Phase III pivotal DRAGON trial in Stargar…
Surgery Partners Q4 Earnings Call Highlights
Surgery Partners (NASDAQ:SGRY) executives told investors that 2025 results reflected “a tale of two halves,” with solid momentum early in the year giving way to second-half headwinds that culminated in a fourth-quarter earnings shortfall concentrated in a small set of surgical hospital markets. Full-year results fell short of expectations as margins compressed For the full […]
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium


